Law360, New York (March 28, 2007, 12:00 AM EDT) -- Congress has introduced several bills that would change regulations regarding drug safety despite moves the U.S. Food and Drug Administration has already made in the wake of the withdrawal of Vioxx and critical reports by groups such as the Institute of Medicine.
But Natasha Leskovsek, special counsel with Heller Ehrman, wondered if the introduction of legislation regarding drug safety is not a case of the cart pulling the horse. “Since Vioxx, the pendulum at the FDA has swung.” In some ways, she said, the legislation would...
FDA Moves To Improve In Wake Of Safety Scrutiny
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
